CDKN2A and acute lymphoblastic leukemia: Among the B-ALL cohort, the presence of the CDKN2A/2B deletion was associated with inferior outcomes (EFS 65.3% vs. 93.6% for the non-deleted B-ALL subgroup, p < 0.001) and a relapse rate of 24.5% vs. 5.8%, respectively (p < 0.001).